The DNA sequencing company also cut its 2025 earnings outlook to reflect the impact of tariffs on its business.

Good day, ladies and gentlemen, and welcome to the first-quarter 2025 Illumina earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would ...

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...

Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...

Q1 2025 Management View CEO Jacob Thaysen highlighted that Q1 revenue and EPS came in at the upper end of guidance. He emphasized the strong performance of the NovaSeq X instruments, with over 60 ...

Wall Street analysts forecast that Illumina (ILMN) will report quarterly ... of analysts suggests that 'Revenue- Product revenue- Instruments' will likely reach $108.95 million.

Discover Standard BioTools' Q1 2025 earnings insights: strategic proteomics growth, Illumina partnership potential, revenue guidance, and ...

and sequencing on an Illumina instrument. Data processing of FASTQ files and analysis using open-source Salmon software, or Cellecta Bioinformatics services to obtain the gene counts and study the ...

The global In Vitro Diagnostics Market, valued at US$100,769.3 million in 2024, is forecasted to grow at a robust CAGR of 7.6%, reaching US$109 ...

Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended ...

Detailed price information for Texas Instruments (TXN-Q) from The Globe and Mail including charting and trades.